Ruxolitinib cream received an expanded approval to treat patients as young as 2 years old with non-immunocompromised mild to ...

The FDA has expanded the indication of Incyte’s Opzelura (ruxolitinib) cream to include children aged two to 11 years with ...

While everyone else queued at Pret , I'd duck into Marshall Street Leisure Centre, a secret tucked-away bit of Soho where the ...

Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales ...

Janine Tugonon's name is once again making headlines, not for pageant-related updates, but for her candid revelations about ...

Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to ...

FDA approves Incyte's Opzelura cream for children aged two and older with atopic dermatitis, expanding its use beyond teens ...

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis ...

Incyte (INCY) “announced that the FDA has approved Opzelura cream 1.5%, a topical Janus kinase inhibitor, for the short-term and non-continuous ...

The U.S. Food and Drug Administration has approved Incyte's eczema treatment for children aged between 2 and 11 years, the ...

Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients.

Adults with atopic dermatitis, whether diagnosed during childhood or adulthood, experienced higher rates of suicidal thoughts ...